Larimar Therapeutics Q2 2024 GAAP EPS $(0.34) Misses $(0.32) Estimate, As Of June 30, 2024, Larimar Therapeutics Had Cash, Cash Equivalents And Marketable Securities Totaling $226.1M, Which Provides Projected Cash Runway Into 2026
Portfolio Pulse from Benzinga Newsdesk
Larimar Therapeutics reported a Q2 2024 GAAP EPS of $(0.34), missing the $(0.32) estimate. As of June 30, 2024, the company had $226.1M in cash, cash equivalents, and marketable securities, providing a projected cash runway into 2026.
August 07, 2024 | 11:16 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Larimar Therapeutics reported a Q2 2024 GAAP EPS of $(0.34), missing the $(0.32) estimate. The company has $226.1M in cash, providing a runway into 2026.
The EPS miss is a negative indicator for short-term stock performance. However, the strong cash position provides some long-term stability.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100